Evaxion Biotech Analyst Ratings

Benzinga Analyst Ratings ·  Nov 17, 2022 08:36
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/17/2022 397.74% Oppenheimer $16 → $11 Maintains Outperform
07/18/2022 623.98% Oppenheimer → $16 Assumes → Outperform
03/02/2021 714.48% Oppenheimer → $18 Initiates Coverage On → Outperform

What is the target price for Evaxion Biotech (EVAX)?

The latest price target for Evaxion Biotech (NASDAQ: EVAX) was reported by Oppenheimer on November 17, 2022. The analyst firm set a price target for $11.00 expecting EVAX to rise to within 12 months (a possible 397.74% upside). 2 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Evaxion Biotech (EVAX)?

The latest analyst rating for Evaxion Biotech (NASDAQ: EVAX) was provided by Oppenheimer, and Evaxion Biotech maintained their outperform rating.

When is the next analyst rating going to be posted or updated for Evaxion Biotech (EVAX)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evaxion Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evaxion Biotech was filed on November 17, 2022 so you should expect the next rating to be made available sometime around November 17, 2023.

Is the Analyst Rating Evaxion Biotech (EVAX) correct?

While ratings are subjective and will change, the latest Evaxion Biotech (EVAX) rating was a maintained with a price target of $16.00 to $11.00. The current price Evaxion Biotech (EVAX) is trading at is $2.21, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment